SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte,
Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson,
chairman and chief executive officer, will present at the Canaccord
Genuity Medical Technologies & Diagnostics Forum on Thursday, November
9, 2017 at 3:00 p.m. Eastern Time in New York, NY.
The live webcast from the Canaccord Genuity Forum and subsequent replay
may be accessed by visiting Veracyte's website at http://investor.veracyte.com.
The replay of the webcast will be available shortly after conclusion of
the presentation and archived on the company's website for 90 days
following the presentation.
About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is
providing trustworthy and actionable answers that fundamentally improve
patient care when current diagnostic tests are uncertain. The company's
products uniquely combine genomic technology, clinical science and
machine learning to provide answers that give physicians and patients a
clear path forward without risky, costly surgery that is often
unnecessary. Since its founding in 2008, Veracyte has commercialized
three genomic tests, which are transforming the diagnosis of thyroid
cancer, lung cancer and idiopathic pulmonary fibrosis and collectively
target a $2 billion market opportunity. Veracyte is based in South San
Francisco, California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Veracyte and the Veracyte logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005448/en/
Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
or
Investors:
Jackie
Cossmon, 650-243-6371
jackie@veracyte.com
Source: Veracyte, Inc.
News Provided by Acquire Media